Naltrexone is a Mu-, Kappa and Delta-Receptor Antagonist. It has a stronger affinity to the opioid receptors than any opioid. It is indicated as adjunctive therapy in the maintenance of formerly opioid dependent patients who have ceased the use of opioids such as e.g. Heroin or Morphine. Naltrexone is also indicated in the treatment of alcohol dependence, as a component of a comprehensive psychotherapeutic or psychological alcoholism counselling program to support abstinence and reduce the risk of relapse. Target groups are Drug Treatment Centres, psychiatrists and physicians treating former opioid- or alcohol addicts.
Country-specific or regional distribution contract
Dr. Juerg Fehlmann
Business Development Manager
OrPha Swiss is looking of in - and out-licensing opportunities in the field of anaesthesia, intensive care, neurology, pulmonary hypertension and addiction medicineView profile
Clients in focus...